July 9 Financial Quick Takes: ADC tops off megaround with $27M; plus Genmab, GNS, StemRIM and more

ADC closes expanded E round at $303M
ADC Therapeutics S.A. (Lausanne, Switzerland) raised an additional $27 million in its expanded series E round, which closed at $303 million. In June, the developer of antibody-drug conjugates announced a $76 million extension to the round; ADC had initially announced a $200 million first close in 2017. A U.S.-based institutional investor contributed $25 million to the latest installment, and existing investors provided the balance (see "ADC Adds $76M to E Round"; "Pays to Stay Private").

Genmab NASDAQ listing could raise over $500M
Genmab A/S (CSE:GEN; Pink:GMXAY) amended its registration statement and now expects to sell 27.8 million ADSs at a maximum price of $18.11 per ADS on NASDAQ, which would raise $503.5 million and value the Danish biotech at $11.7 billion. The deal is expected to price during the week beginning July 15. At March 31, Genmab had DKK1.18 billion ($177 million) in cash...